NuuVive

Compounds explained

What is MOTS-c? What it has been studied for

NuuVive Journal · · 6 min read

A quiet analytical laboratory at dawn

Short answer

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide naturally encoded in mitochondrial DNA. Discovered in 2015, it has been studied primarily in animal and cell models of metabolism, obesity, exercise adaptation, and osteoporosis. While a phase 2a clinical trial has been registered to investigate its role in insulin sensitivity, it is not an approved drug and lacks large-scale human trial data.

Key takeaways

  • MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in 2015.
  • Research is largely confined to cell cultures and animal models of metabolism, obesity, and exercise adaptation.
  • There are no completed, large-scale human clinical trials evaluating synthetic MOTS-c.
  • It is not FDA-approved, though a 2026 HHS policy temporarily permits pharmacy compounding under strict conditions.
  • A valid lab report for MOTS-c must confirm its exact 2174.6 g/mol molecular weight and a high purity percentage.

The basement blueprint: where MOTS-c comes from

Look at the marketing copy for most research compounds and you will see a lot of grand claims about cellular energy. Look at the actual published literature for MOTS-c, and you will find a highly specific, 16-amino-acid sequence that geneticists did not even know existed before 2015. The gap between those two worlds is wide, and navigating it requires ignoring the noise and looking at the chemistry.

Most peptides and proteins are built from instructions in the cell's nucleus, which acts as the main architectural blueprint. MOTS-c comes from the basement. It is classified as a mitochondrial-derived peptide (MDP). Mitochondria, the structures responsible for cellular respiration, possess their own tiny, circular loop of DNA. For decades, researchers believed they understood exactly what this mitochondrial genome coded for.

That changed when a team led by Changhan Lee at the Pinchas Cohen laboratory (USC Davis School of Gerontology) discovered a short open reading frame hidden within the 12S ribosomal RNA gene 1. This specific genetic sequence codes for MOTS-c, which stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c. The discovery was a surprise to geneticists, opening up a new way of looking at how mitochondria might communicate stress signals to the rest of the cell. For another example of a molecule aimed at this cellular machinery, you can explore the structural and trial history of SS-31.

The resulting molecule is exactly 16 amino acids long, with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. It is a highly specific structure, and any variation in that sequence means you are no longer looking at MOTS-c. To see how this precise sequence differs from a shorter synthetic counterpart, you can explore the research differences between MOTS-c and SS-31.

Metabolism and the AMPK pathway

Researchers investigate MOTS-c primarily as a metabolic regulator and signaling molecule. The bulk of this research takes place in petri dishes and rodent cages. A major focus of these preclinical studies is the AMPK (AMP-activated protein kinase) pathway. AMPK acts as a cellular energy sensor, activating when cellular energy levels drop.

In laboratory settings, scientists have studied MOTS-c in mice fed a high-fat diet to observe its interaction with cellular glucose flux and fat metabolism 4. These animal models are used to track markers such as fat accumulation and the cellular ability to switch between fuel sources under metabolic stress.

It is important to understand the nature of these studies. When researchers publish a paper on MOTS-c and metabolism, they are documenting biochemical reactions in highly controlled, genetically uniform animal populations. They are mapping pathways, not establishing guidelines for the public.

Exercise, aging, and osteoporosis models

Alongside metabolic research, scientists have investigated MOTS-c in animal models of physical endurance and stress adaptation. Researchers have measured endurance markers in mice to see how the peptide interacts with skeletal muscle under exertion. In parallel, small human observational studies have measured naturally occurring (endogenous) MOTS-c levels in blood and muscle tissue following exercise.

Observational studies are exactly what they sound like: researchers observe what the organism is already doing. They measure the MOTS-c that a participant naturally produces after a session on a stationary bike. This is fundamentally different from introducing a synthetic peptide into a trial participant.

The compound has also been investigated in animal models of aging and osteoporosis. Studies involving young, middle-aged, and old mice have explored its impact on age-related physical decline and systemic metabolic homeostasis. In osteoporosis research, scientists have used ovariectomy-induced bone loss models in mice to evaluate the role of MOTS-c in the AMPK-dependent suppression of osteoclast activity (the cells that break down bone tissue). If exploring the intersection of peptides and aging models interests you, it is worth looking at the Russian origins and research profile of Epitalon.

Finally, cell culture and animal models, such as NOD mice, have been used to investigate its interactions with immune cells, pro-inflammatory cytokines, and macrophages. All of this remains strictly in preclinical investigation.

The human evidence gap

If you read enough online forums, you might assume MOTS-c has a mountain of clinical data behind it. It does not. While animal and cellular data exist, there are currently no completed, large-scale, randomized, placebo-controlled human clinical trials with published, peer-reviewed data evaluating synthetic MOTS-c for obesity, metabolic syndrome, diabetes, or aging.

There is, however, movement in early-stage clinical research. A Phase 2a clinical trial, titled MOTS-MET, has been registered to evaluate the effect of MOTS-c on insulin sensitivity 5. The trial plans to study 120 human adults with prediabetes and overweight or obesity, measuring insulin sensitivity via an oral glucose tolerance test. Until trials like this are completed, peer-reviewed, and replicated, the human evidence base remains thin. If you are curious about another 16-amino-acid fragment that actually reached phase 2b trials, you can read the research history of AOD-9604.

The 2026 legal and compounding status

MOTS-c is not FDA-approved for any medical condition or indication. It has not passed the FDA's clinical trial or new drug application (NDA) processes. However, its regulatory status shifted significantly in 2026 regarding pharmacy compounding.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 7 to 5 to recommend adding MOTS-c to the 503A Bulks List for compounding, specifically covering obesity and osteoporosis research areas. This vote was non-binding and awaits final FDA rulemaking. To bridge the gap, HHS stepped in.

On October 28, 2026, HHS announced a temporary, interim enforcement discretion policy covering MOTS-c and five other peptides 2. Under this new peptide policy, HHS does not intend to pursue enforcement action against state-licensed pharmacies compounding MOTS-c. This is strictly conditional upon having a valid patient-specific prescription and meeting ten rigorous manufacturing, labeling, and FDA-registered sourcing requirements. This policy acts as a stopgap and is not an FDA approval.

A flowchart showing the July 2026 PCAC vote, the October 28, 2026 HHS policy, and awaiting final FDA rulemaking.
The sequence of regulatory events for MOTS-c compounding in 2026.

Reading a MOTS-c lab report

If you are sourcing MOTS-c for laboratory research, the vendor's marketing claims are irrelevant. The only document that matters is the Certificate of Analysis (CoA) from an independent, third-party analytical laboratory. A lot number is the vial's passport; if the CoA does not match the lot number on the vial, the document is useless.

A proper lab test relies on two main instruments. The first is Mass Spectrometry (MS), which weighs the molecules in the sample. The molecular weight of MOTS-c is exactly 2174.6 g/mol, and its chemical formula is C101H152N28O22S2 3. The mass spectrometer must show a result that matches 2174.6 g/mol. If the number is off, the sequence is wrong, and the vial does not contain MOTS-c.

The second instrument is High-Performance Liquid Chromatography (HPLC), which measures purity. A chromatogram is a race where every impurity has to cross the finish line in public. You want to see one massive, sharp peak representing the MOTS-c, with very few tiny bumps trailing behind it. A high-quality research supplier will provide these exact figures openly. You can check the current price, stock, and measured purity levels on NuuVive's MOTS-c.

Questions

Is MOTS-c an approved drug?

No. MOTS-c is not FDA-approved for any indication. It is currently a research compound studied in preclinical models and early-stage clinical trials.

What is the difference between MOTS-c and NAD+?

While both are studied in the context of cellular energy, they are entirely different molecules. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, whereas NAD+ is a coenzyme found in all living cells that facilitates redox reactions.

Why is MOTS-c called a mitochondrial-derived peptide?

Unlike most peptides that are encoded by DNA in the cell's nucleus, MOTS-c is encoded by a specific gene (the 12S rRNA gene) located within the mitochondria's own distinct circular DNA.

What does the 2026 HHS policy mean for MOTS-c?

The October 28, 2026 HHS policy allows state-licensed pharmacies to compound MOTS-c under strict enforcement discretion. It requires a valid prescription and adherence to rigorous sourcing and manufacturing standards, acting as a temporary measure pending final FDA rulemaking.

Sources

  1. nih.gov. National Library of Medicine
  2. HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides | Insights | Holland & Knight. hklaw.com
  3. PubChem. National Library of Medicine
  4. MOTS-c review - Search Results. National Library of Medicine
  5. ClinicalTrials.gov. clinicaltrials.gov